Stomach cancer drug combo trial halted midway
Disease control
Terminated
This study tested a new drug called DKN-01 combined with tislelizumab and chemotherapy for people with advanced stomach or gastroesophageal junction cancer that could not be removed by surgery. The trial enrolled 247 adults who had not received prior treatment or whose cancer had…
Phase: PHASE2 • Sponsor: Leap Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC